V-073 demonstrates potent, broad-spectrum in vitro antiviral activity against a wide range of polioviruses, supporting its potential as a candidate for posteradication management.
Answers are grounded in this paper and cite their sources.
Supports V-073 development for post-eradication poliovirus control; leaves open need for in vivo and clinical validation.
V-073, an enterovirus capsid inhibitor, was evaluated for its spectrum of antipoliovirus activity. V-073 inhibited all 45 polioviruses tested in a virus-induced cytopathic effect protection assay, with 50% effective concentration (EC50) values ranging from 0.003 to 0.126 microM. Ninety percent of the polioviruses tested were inhibited at EC(50)s of < or = 0.076 microM (MIC90 = 32 ng/ml). V-073 is a promising antiviral candidate for the posteradication management of poliovirus incidents.
No takes yet. Share an insight, caveat, or question.
Oberste et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: